Department of Nephrology and Hypertension, University Medical Centre Utrecht, Utrecht, The Netherlands.
Surgical, Medical, Dental, Morphology Sciences, Transplant, Oncology and Regenerative Medicine Department, Division of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Semin Dial. 2022 Nov;35(6):481-497. doi: 10.1111/sdi.13097. Epub 2022 Jun 1.
Clinical application of continuous flow peritoneal dialysis (CFPD) has been explored since the 1960s, but despite anticipated clinical benefits, CFPD has failed to gain a foothold in clinical practice, among others due to the typical use of two catheters (or a dual-lumen catheter) and large dialysate volumes required per treatment. Novel systems applying CFPD via the existing single-lumen catheter using rapid dialysate cycling may solve one of these hurdles. Novel on-demand peritoneal dialysate generation systems and sorbent-based peritoneal dialysate regeneration systems may considerably reduce the storage space for peritoneal dialysate and/or the required dialysate volume. This review provides an overview of current evidence on CFPD in vivo. The available (pre)clinical evidence on CFPD is limited to case reports/series with inherently nonuniform study procedures, or studies with a small sample size, short follow-up, and no hard endpoints. Small solute clearance appears to be higher in CFPD compared to conventional PD, in particular at dialysate flows ≥100 mL/min using two single-lumen catheters or a double-lumen catheter. Results of CFPD using rapid cycling via a single-lumen catheter are too preliminary to draw any conclusions. Continuous addition of glucose to dialysate with CFPD appears to be effective in reducing the maximum intraperitoneal glucose concentration while increasing ultrafiltration efficiency (mL/g absorbed glucose). Patient tolerance may be an issue since abdominal discomfort and sterile peritonitis were reported with continuous circulation of the peritoneal dialysate. Thus, well-designed clinical trials of longer duration and larger sample size, in particular applying CFPD via the existing catheter, are urgently required.
连续流动腹膜透析(CFPD)的临床应用自 20 世纪 60 年代就已经开始探索,但尽管有预期的临床获益,CFPD 仍未能在临床实践中立足,部分原因是其典型应用需要使用两根导管(或双腔导管),并且每次治疗所需的透析液量较大。通过现有单腔导管应用 CFPD 并采用快速透析液循环的新型系统可能可以解决其中一个障碍。新型按需腹膜透析液生成系统和基于吸附剂的腹膜透析液再生系统可以大大减少腹膜透析液的储存空间和/或所需的透析液量。本文综述了 CFPD 的体内现有证据。目前关于 CFPD 的可用(临床前)证据仅限于研究程序不一致的病例报告/系列,或样本量小、随访时间短且无硬性终点的研究。与传统 PD 相比,CFPD 中小分子溶质的清除率似乎更高,特别是在使用两根单腔导管或双腔导管时透析液流速≥100ml/min。通过单腔导管进行快速循环的 CFPD 结果还为时过早,无法得出任何结论。在 CFPD 中持续向透析液中添加葡萄糖似乎可以有效降低腹腔内最大葡萄糖浓度,同时提高超滤效率(mL/g 吸收葡萄糖)。由于连续循环腹膜透析液可能会引起腹部不适和无菌性腹膜炎,因此患者的耐受性可能是一个问题。因此,迫切需要设计更长时间和更大样本量的临床试验,特别是通过现有的导管应用 CFPD。